{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:13:06Z","timestamp":1747714386554,"version":"3.40.5"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>Unter der Allgemeinbev\u00f6lkerung in Nordschweden lag die Pr\u00e4valenz des Raynaud-Ph\u00e4nomens (RP) bei 12%; dies wirkte sich bei auch in k\u00e4lterer Umgebung arbeitenden Berufst\u00e4tigen nicht auf die Dauer und H\u00e4ufigkeit von Erkrankungen und den Lebensunterhalt aus. Patienten mit RP im Rahmen einer Systemischen Sklerose (SSc) hatten zu 25% Beeintr\u00e4chtigungen in der Gebrauchsf\u00e4higkeit der H\u00e4nde, mit Tendenz zur Verschlechterung, allerdings oft durch Sehnensch\u00e4den.<\/jats:p><jats:p>Patienten mit niedrigerem Body-Mass-Index (BMI) sind h\u00e4ufiger vom RP betroffen. Es tritt auch \u00f6fter auf, wenn Patienten Gewicht verlieren, durchaus auch als Folge von Di\u00e4ten. Auch bei niedrigen Au\u00dfentemperaturen kommt das RP h\u00e4ufig vor. Diese Abh\u00e4ngigkeit betrifft nicht nur das prim\u00e4re RP \u2013 ein klarer Zusammenhang l\u00e4sst sich auch bei zugrunde liegender SSc nachweisen.<\/jats:p><jats:p>Angstst\u00f6rungen und Depressionen sind bei Menschen mit RP \u00f6fter anzutreffen als in der Normalbev\u00f6lkerung \u2013 und k\u00f6nnen umgekehrt die Entstehung eines RP offenbar mit hervorrufen. Auch bei Diagnose einer peripheren sensorischen Polyneuropathie tritt das RP h\u00e4ufiger auf. Mehrere Medikamente k\u00f6nnen zur Liste der RP-Verursacher addiert werden, auch Silikon aus Brustimplantaten.<\/jats:p><jats:p>Bei neu aufgetretenem RP kann es sich um eine Fr\u00fchform der SSc (VEDOSS) handeln. Die Nagelfalz-Kapillarmikroskopie ist ein wichtiger Baustein f\u00fcr die Diagnose der SSc. Um diese zu stellen, sind die Kapillarver\u00e4nderungen allein aber nicht hinreichend. Treten keine weiteren Krankheitsmerkmale hinzu, kann man nach 5\u201310 Jahren wohl von einem prim\u00e4ren RP ausgehen.<\/jats:p><jats:p>Beim prim\u00e4ren RP stehen k\u00e4lteprophylaktische Ma\u00dfnahmen im Vordergrund. Beheizbare Handschuhe helfen, ein RP zu reduzieren. Dabei scheint die Verwendung von Silberf\u00e4den keine zus\u00e4tzlichen Vorteile zu bringen. Zur medikament\u00f6sen Behandlung bei der SSc sind neue Leitlinien der EULAR (European Alliance of Associations for Rheumatology) und der BSR (British Society for Rheumatology) erschienen. Kalziumkanalblocker (CCB) werden zur Initialtherapie empfohlen, daneben Phosphodiesterase-5-Hemmer (PDE5-Hemmer) und Prostanoide. Beim Auftreten von Fingernekrosen bringen CCB offenbar keine Vorteile. Hier kann neben PDE5-Hemmern, Prostanoiden und dem Endothelin-Antagonisten Bosentan auch Botulinum-A-Toxin lokal angewendet werden \u2013 empfohlen wird dies bisher nur von der britischen Leitlinie. Beim RP ist ein erheblicher Placebo-Effekt zu ber\u00fccksichtigen. Euphorischen Fallstudien stehen oft ern\u00fcchternde kontrollierte Studien gegen\u00fcber. Eine lokale Applikation von aus Fettgewebe gewonnenen Fett-, Bindegewebe- und Stammzellen k\u00f6nnte bei RP-Patienten mit SSc deren Schmerzen und die Gebrauchsbeeintr\u00e4chtigung der H\u00e4nde bessern.<\/jats:p>","DOI":"10.1055\/a-2365-0537","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T23:08:26Z","timestamp":1747696106000},"page":"661-667","source":"Crossref","is-referenced-by-count":0,"title":["Update Raynaud-Syndrom"],"prefix":"10.1055","volume":"150","author":[{"given":"Ludwig","family":"Caspary","sequence":"additional","affiliation":[{"name":"Angiologische Praxis, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12995-022-00354-2","article-title":"The impact of Raynaud\u2019s phenomenon on work ability \u2013 a longitudinal study","volume":"17","author":"A Stjernbrandt","year":"2022","journal-title":"J Occup Med Toxicol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003216","article-title":"Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets","volume":"10","author":"E De Lorenzis","year":"2024","journal-title":"RMD Open"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/03009742.2020.1780310","article-title":"Low body weight and involuntary weight loss are associated with Raynaud\u2019s phenomenon in both men and women","volume":"50","author":"AE Abdulle","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1016\/S2665-9913(24)00189-9","article-title":"The association of outdoor temperature and self-reported Raynaud\u2019s phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study","volume":"6","author":"G Virgili-Gervais","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1017\/S1352465823000620","article-title":"Psychological factors in symptom severity and quality of life in Raynaud\u2019s phenomenon","volume":"52","author":"D Irving","year":"2024","journal-title":"Behav Cogn Psychother"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jaad.2023.12.015","article-title":"Depression in patients with Raynaud's phenomenon: A case-control study in the National Institutes of Health\u2019s All of Us Research Program","volume":"90","author":"GF Chen","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/23971983231155945","article-title":"Prevalence of Raynaud\u2019s phenomenon in patients with peripheral neuropathy","volume":"8","author":"R Shukla","year":"2023","journal-title":"J Scleroderma Relat Disord"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152521","article-title":"Clinically relevant differences between primary Raynaud\u2019s phenomenon and secondary to connective tissue disease","volume":"68","author":"S Di Donato","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Very Early Diagnosis of Systemic Sclerosis collaborators. Progression of patients with Raynaud\u2019s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"S Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/rheumatology\/keac006","article-title":"Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort","volume":"61","author":"VS Siqueira","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/1744666X.2024.2313642","article-title":"Re-evaluation of nailfold capillaroscopy in discriminating primary from secondary Raynaud\u2019s phenomenon and in predicting systemic sclerosis: a randomised observational prospective cohort study","volume":"20","author":"MC Amaral","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"S 01","key":"ref12","doi-asserted-by":"crossref","first-page":"SI74","DOI":"10.1093\/rheumatology\/keac243","article-title":"The effect of silver fibre gloves on Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial","volume":"62","author":"SIE Liem","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/mr\/roac116","article-title":"Arm heating to relieve Raynaud\u2019s phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial","volume":"33","author":"A Watanabe","year":"2023","journal-title":"Mod Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"F Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for management of systemic sclerosis","volume":"63","author":"CP Denton","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-023-06796-1","article-title":"The effect of calcium channel blockers on digital ulcers in systemic sclerosis: data from a prospective cohort study","volume":"43","author":"L Ross","year":"2024","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014089","article-title":"Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud\u2019s phenomenon","volume":"11","author":"N Maltez","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e5885","DOI":"10.1097\/GOX.0000000000005885","article-title":"Toxin for Treating Raynaud Conditions in Hands (The TORCH Study): A Systematic Review and Meta-analysis","volume":"12","author":"E Geary","year":"2024","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00403-024-02864-x","article-title":"Efficacy and safety of botulinum toxin in treating scleroderma-associated raynaud\u2019s phenomenon: a systematic review and meta-analysis","volume":"316","author":"A Elrosasy","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.42342","article-title":"Efficacy and Safety of Botulinum Toxin in Adults with Raynaud\u2019s Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","volume":"75","author":"P Senet","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152087","article-title":"Placebo response in Raynaud\u2019s Phenomenon clinical trials: The prominent role of regression towards the mean: Placebo response in Raynaud\u2019s Phenomenon","volume":"57","author":"M Roustit","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/rheumatology\/keae049","article-title":"A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud\u2019s","volume":"64","author":"G Tornling","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/rheumatology\/keab584","article-title":"Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis","volume":"61","author":"A Daumas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.55563\/clinexprheumatol\/ycy3k7","article-title":"Autologous fat or adipose-derived stem cell grafting in systemic sclerosis treatment: a systematic review and meta-analysis","volume":"41","author":"Y Cao","year":"2023","journal-title":"Clin Exp Rheumatol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2365-0537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T23:08:31Z","timestamp":1747696111000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2365-0537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,5,19]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2365-0537","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}